Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: VNDA: No change in strategy (See Vol. 1, Edition 2). […]
Week’s Option Activity (10/10~10/16)
The following stocks had notable activity in their options during the past week(s): $XOMA (10/10): 3,000 OCT 5.0 strike Calls were bought (stock at $4.69) for 0.50 or $150,000. This appears to be an opening trade (thus highly speculative given proximity to expiration). Buyer makes money if stock trades above $5.50 by expiration. $PATH (10/10): […]
Catalyst Watch – Vol. 1, Edition 4 (10/11/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Waiting for briefing docs… More to follow on this […]
Week’s Option Activity (9/30~10/4)
The following stocks had notable activity in their options during the past week: $ACHN (10/1): Substantial Call activity (both near and long term dated options). 28,500 JAN15 5.0/(7.5) strike long Call spreads (stock at $2.66) were bought for 0.40 or $1.14 million. Buyer makes money if stock trades north of $5.40 by January 2015 expiration […]
Catalyst Watch – Vol. 1, Edition 3 (10/2/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Stock continues to climb (now at $6.85). No delay […]
Week’s Option Activity (9/23~9/27)
The following stocks had notable activity in their options during the past week(s): $EDAP (9/23): Bullish long term Call buys. 750 FEB14 2.50 strike Calls (stock at $2.68) were bought for 0.60 or $45,000. Also 750 MAY14 2.50 strike Calls were bought for 0.70 or $52,500. For these trades, buyer makes money if the stock […]
Catalyst Watch – Vol. 1, Edition 2 (9/26/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: The stock is up slightly ($6.58) from our last […]
Week’s Option Activity (9/16~9/20)
The following stocks had notable activity in their options during the past week: $GERN (9/17): 5,000 OCT 2.00 strike Puts (stock at $2.26) were purchased for 0.14 or $70,000. This appears to be an opening trade where the buyer makes money if the shares trade below $1.86 by expiration. This could also be a long […]
Catalyst Watch – Vol. 1, Edition 1 (9/20/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: Ticker: VNDA ($13.16) Catalyst: AdCom for Tasimelteon Date/Timing: November 14, 2013 CRG View: Bearish Cash: $151.9m […]
Week’s Option Activity (9/3~9/13)
The following stocks had notable activity in their options during the past week(s): $RPRX (9/3): Several large trades today. First, 1,580 OCT 30.0 strike Calls (stock at $21.14) were bought for 1.20 or $189,600 – buyer makes money if stock trades north of $31.20 by October expiration. Second, what appears to be a SEP ratioed […]
Week’s Option Activity (8/26~8/30)
The following stocks had notable activity in their options during the past week: $IMMU (8/26): Big activity in JAN14 Calls. 1,949 JAN14 5.0 strike Calls (stock at $6.15) were purchased for 1.60 or total cost of $311,840. Buyer makes money as long as stock is greater than $6.60 by JAN14 expiration. Also in a separate […]
Week’s Option Activity (8/19~8/22)
The following stocks had notable activity in their options during the past week: $AMRN (8/19): 5,000 OCT 7.0 strike Calls (stock at $6.00) were sold for 0.87 or $435,000 total proceeds. Seller makes money as long as stock trades below $7.87 by expiration. This trade may also be a current long stockholder selling Calls to […]
PGNX – A Hidden Bullish Divergence
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with chronic pain. On July 27, 2012 Salix (SLXP) and Progenics received CRL from the FDA regarding the RELISTOR sNDA. But Slaix filed a formal appeal […]
Week’s Option Activity (8/5~8/9)
The following stocks had notable activity in their options during the past week: $PBTH (8/7): Active day in the Calls. 500 AUG 5.0 strike Calls (stock at $6.86) were purchased for 2.05 or $102,500 – buyer makes money if stock trades north of $7.05 by August expiration. Also, 500 FEB14 7.50 strike Calls were sold […]
Week’s Option Activity (7/29~8/2)
The following stocks had notable activity in their options during the past week: $IBB (7/30): 2,500 SEP 190.0/(180.0) strike Put spreads (ETF at $197) were bought for 2.30 or total debit of $575,000. The SEP 190.0 strike Puts were bought for 4.00 and the SEP 180.0 strike Puts were sold for 1.70 against. Buyer makes […]
IBB – Technical Commentary
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times High“, we wanted to maintain our focus on the IBB. In today’s video “IBB – Market Activity” Tony noted a large bearish bet or hedge […]
Week’s Option Activity (7/23~7/27)
The following stocks had notable activity in their options during the past week: $XOMA (7/23): 2,000 SEP/OCT 5.0 strike Call Time spreads (stock at $5.08) were bought for 0.35 or $70,000 net debit. The SEP 5.0 strike Calls were sold for 0.60 ($120,000 proceeds) and the SEP 5.0 strike Calls were bought for 0.95 ($190,000 […]
